Compound class:
Synthetic organic
|
|
References |
1. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. (2005)
Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov, 4 (12): 988-1004. [PMID:16341064] |
2. Loijens JC, Anderson RA. (1996)
Type I phosphatidylinositol-4-phosphate 5-kinases are distinct members of this novel lipid kinase family. J Biol Chem, 271 (51): 32937-43. [PMID:8955136] |
3. Persson J, Larsson R, Sterner O, Johansson M. (2011)
Indolyl-substituted pyrazino-quinolines and their use for the treatment of cancer. Patent number: WO2010149944. Assignee: Oncorel Ab.. Priority date: 25/06/2009. Publication date: 24/02/2011. |
4. Saito K, Tolias KF, Saci A, Koon HB, Humphries LA, Scharenberg A, Rawlings DJ, Kinet JP, Carpenter CL. (2003)
BTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activity. Immunity, 19 (5): 669-78. [PMID:14614854] |
5. Semenas J, Hedblom A, Miftakhova RR, Sarwar M, Larsson R, Shcherbina L, Johansson ME, Härkönen P, Sterner O, Persson JL. (2014)
The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer. Proc Natl Acad Sci USA, 111 (35): E3689-98. [PMID:25071204] |